Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -420.14% is 392% below its 5-year average of -85.48%, near the low end of its 5-year range (-420.14%–-38.64%).
228.27% below its 12-month average of -127.99%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -54.44%.
RETURN ON ASSETS (ROA)
-420.14%
RETURN ON ASSETS (ROA) AVG TTM
-127.99%
RETURN ON ASSETS (ROA) AVG 3Y
-97.65%
RETURN ON ASSETS (ROA) AVG 5Y
-85.48%
RETURN ON ASSETS (ROA) AVG 10Y
-104.68%
RETURN ON ASSETS (ROA) AVG 15Y
-62.05%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-228.27%
CURRENT VS 3Y AVG
-330.25%
CURRENT VS 5Y AVG
-391.53%
CURRENT VS 10Y AVG
-301.35%
CURRENT VS 15Y AVG
-577.06%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-1203.16%
vs the sector median at left
Tempest Therapeutics, Inc.
Market Cap
$12.43M
Return on Assets (ROA)
-420.14%
TTM Avg
-127.99%
3Y Avg
-97.65%
5Y Avg
-85.48%
Market Cap
$12.28M
Return on Assets (ROA)
-216.84%
TTM Avg
-118.20%
3Y Avg
-6127.40%
5Y Avg
-4092.56%
Market Cap
$12.56M
Return on Assets (ROA)
-49.12%
TTM Avg
-29.80%
3Y Avg
-67.98%
5Y Avg
-117.36%
Market Cap
$12.22M
Return on Assets (ROA)
-60.93%
TTM Avg
-160.25%
3Y Avg
-205.49%
5Y Avg
-152.09%
Market Cap
$12.60M
Return on Assets (ROA)
-47.98%
TTM Avg
-31.15%
3Y Avg
-42.27%
5Y Avg
-34.21%
Market Cap
$12.24M
Return on Assets (ROA)
-77.94%
TTM Avg
-178.68%
3Y Avg
-1009.31%
5Y Avg
-2782.57%
Market Cap
$11.94M
Return on Assets (ROA)
-13.01%
TTM Avg
-15.22%
3Y Avg
-24.53%
5Y Avg
-20.43%
Market Cap
$11.76M
Return on Assets (ROA)
-26.45%
TTM Avg
-58.62%
3Y Avg
-47.64%
5Y Avg
-51.16%
Market Cap
$13.14M
Return on Assets (ROA)
-85.85%
TTM Avg
-102.78%
3Y Avg
-95.22%
5Y Avg
-76.09%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempest Therapeutics, Inc. (TPST) | $12.43M | -420.14% | -127.99% | -97.65% | -85.48% |
| Lantern Pharma Inc. (LTRN)vs › | $12.28M | -216.84% | -118.20% | -6127.40% | -4092.56% |
| Dare Bioscience, Inc. (DARE)vs › | $12.56M | -49.12% | -29.80% | -67.98% | -117.36% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.22M | -60.93% | -160.25% | -205.49% | -152.09% |
| Cytosorbents Corporation (CTSO)vs › | $12.60M | -47.98% | -31.15% | -42.27% | -34.21% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.24M | -77.94% | -178.68% | -1009.31% | -2782.57% |
| IRIDEX Corporation (IRIX)vs › | $11.94M | -13.01% | -15.22% | -24.53% | -20.43% |
| Biofrontera Inc. (BFRI)vs › | $11.76M | -26.45% | -58.62% | -47.64% | -51.16% |
| IN8bio, Inc. (INAB)vs › | $13.14M | -85.85% | -102.78% | -95.22% | -76.09% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.21M | -32.53% | -31.07% | -30.77% | -29.89% |
ROA
-420.1%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -155.11% |
| 2024-12-31 | -100.86% |
| 2023-12-31 | -57.15% |
| 2022-12-31 | -77.48% |
| 2021-12-31 | -38.64% |
| 2020-12-31 | -83.62% |
| 2019-12-31 | -59.45% |
| 2018-12-31 | -32.34% |
| 2017-12-31 | -426.90% |
| 2016-12-31 | -67.13% |
| 2015-12-31 | -52.82% |
| 2014-12-31 | -75.52% |
| 2013-12-31 | -61.09% |
| 2012-12-31 | -41.17% |
| 2011-12-31 | -59.43% |
